HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy.

Abstract
Cellular human immunodeficiency virus type 1 (HIV-1) DNA may be considered a marker of disease progression with significant predictive power, but published data on its correlation with plasma HIV RNA levels and CD4 counts in acute and chronic patients are not conclusive. We evaluated a cohort of 180 patients naïve for antiretroviral therapy before the beginning of treatment and after a virological response in order to define the indicators correlated with HIV DNA load decrease until undetectability. The following variables were evaluated as continuous variables: age, CD4 cell count and log(10) HIV DNA level at baseline and follow-up, and baseline log(10) HIV RNA level. Primary HIV infection at the start of therapy, an HIV RNA level at follow-up of <2.5 copies/ml, origin, gender, and transmission risk were evaluated as binary variables. The decline of HIV DNA values during effective therapy was directly related to baseline HIV DNA and HIV RNA values, to an increase in the number of CD4 cells, and to the achievement of an HIV RNA load of <2.5 copies/ml. An undetectable cellular HIV DNA load was achieved by 21.6% of patients at the follow-up time point and correlated significantly with lower baseline cellular HIV DNA values and with being in the primary stage of infection when therapy started. In conclusion, early treatment facilitated the achievement of undetectable levels of plasma viremia and cellular HIV DNA and a better recovery of CD4 lymphocytes. HIV DNA levels before and during highly active antiretroviral therapy may be used as a new tool for monitoring treatment efficacy.
AuthorsSaverio Giuseppe Parisi, Samantha Andreis, Carlo Mengoli, Renzo Scaggiante, Roberto Ferretto, Vinicio Manfrin, Mario Cruciani, Mario Giobbia, Caterina Boldrin, Monica Basso, Massimo Andreoni, Giorgio Palù, Loredana Sarmati
JournalJournal of clinical microbiology (J Clin Microbiol) Vol. 50 Issue 2 Pg. 258-63 (Feb 2012) ISSN: 1098-660X [Electronic] United States
PMID22135262 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-HIV Agents
  • DNA, Viral
  • RNA, Viral
Topics
  • Adult
  • Aged
  • Anti-HIV Agents (administration & dosage)
  • Antiretroviral Therapy, Highly Active
  • Blood (virology)
  • CD4 Lymphocyte Count
  • DNA, Viral (analysis, genetics)
  • Drug Monitoring (methods)
  • Female
  • HIV Infections (drug therapy, virology)
  • HIV-1 (genetics, isolation & purification)
  • Humans
  • Male
  • Middle Aged
  • Plasma (virology)
  • RNA, Viral (analysis, genetics)
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: